These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 37146924)

  • 1. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
    Qiu YY; Zhang J; Zeng FY; Zhu YZ
    Pharmacol Res; 2023 Jun; 192():106786. PubMed ID: 37146924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease.
    Fougerat A; Montagner A; Loiseau N; Guillou H; Wahli W
    Cells; 2020 Jul; 9(7):. PubMed ID: 32650421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease.
    Choudhary NS; Kumar N; Duseja A
    J Clin Exp Hepatol; 2019; 9(6):731-739. PubMed ID: 31889755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease.
    Puengel T; Liu H; Guillot A; Heymann F; Tacke F; Peiseler M
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages
    Lefere S; Puengel T; Hundertmark J; Penners C; Frank AK; Guillot A; de Muynck K; Heymann F; Adarbes V; Defrêne E; Estivalet C; Geerts A; Devisscher L; Wettstein G; Tacke F
    J Hepatol; 2020 Oct; 73(4):757-770. PubMed ID: 32360434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of peroxisome proliferator-activated receptors in hepatocellular carcinoma.
    Zhao Y; Tan H; Zhang X; Zhu J
    J Cell Mol Med; 2024 Mar; 28(5):e18042. PubMed ID: 37987033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
    Serviddio G; Bellanti F; Vendemiale G
    Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis.
    Mahmoudi A; Butler AE; Jamialahmadi T; Sahebkar A
    Biomed Res Int; 2021; 2021():3654660. PubMed ID: 34988225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Li-Gan-Shi-Liu-Ba-Wei-San improves non-alcoholic fatty liver disease through enhancing lipid oxidation and alleviating oxidation stress.
    Jiang Y; Chen L; Wang H; Narisi B; Chen B
    J Ethnopharmacol; 2015 Dec; 176():499-507. PubMed ID: 26571089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into the Role of PPARβ/δ in NAFLD.
    Chen J; Montagner A; Tan NS; Wahli W
    Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29954129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.
    Boeckmans J; Natale A; Rombaut M; Buyl K; Rogiers V; De Kock J; Vanhaecke T; M Rodrigues R
    Cells; 2019 Dec; 9(1):. PubMed ID: 31877771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation.
    Silva AKS; Peixoto CA
    Cell Mol Life Sci; 2018 Aug; 75(16):2951-2961. PubMed ID: 29789866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease.
    Pawlak M; Lefebvre P; Staels B
    J Hepatol; 2015 Mar; 62(3):720-33. PubMed ID: 25450203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels.
    Yessoufou A; Wahli W
    Swiss Med Wkly; 2010; 140():w13071. PubMed ID: 20842602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of Drug Metabolism by the Interplay of Inflammatory Signaling, Steatosis, and Xeno-Sensing Receptors in HepaRG Cells.
    Tanner N; Kubik L; Luckert C; Thomas M; Hofmann U; Zanger UM; Böhmert L; Lampen A; Braeuning A
    Drug Metab Dispos; 2018 Apr; 46(4):326-335. PubMed ID: 29330220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis.
    Francque S; Verrijken A; Caron S; Prawitt J; Paumelle R; Derudas B; Lefebvre P; Taskinen MR; Van Hul W; Mertens I; Hubens G; Van Marck E; Michielsen P; Van Gaal L; Staels B
    J Hepatol; 2015 Jul; 63(1):164-73. PubMed ID: 25703085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ménage à trois of autophagy, lipid droplets and liver disease.
    Filali-Mouncef Y; Hunter C; Roccio F; Zagkou S; Dupont N; Primard C; Proikas-Cezanne T; Reggiori F
    Autophagy; 2022 Jan; 18(1):50-72. PubMed ID: 33794741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of PPARs in Disease.
    Wagner N; Wagner KD
    Cells; 2020 Oct; 9(11):. PubMed ID: 33126411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: a study in Brazilian patients.
    Domenici FA; Brochado MJ; Martinelli Ade L; Zucoloto S; da Cunha SF; Vannucchi H
    Gene; 2013 Oct; 529(2):326-31. PubMed ID: 23891824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
    Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A
    Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.